- Home
- IMAB vs VIGL Comparison
IMAB vs VIGL Comparison
Compare IMAB & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- VIGL
- Stock Information
- Founded
- IMAB 2014
- VIGL 2020
- Country
- IMAB United States
- VIGL United States
- Employees
- IMAB N/A
- VIGL N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- VIGL Health Care
- Exchange
- IMAB Nasdaq
- VIGL Nasdaq
- Market Cap
- IMAB 200.9M
- VIGL 134.9M
- IPO Year
- IMAB 2020
- VIGL 2022
- Fundamental
- Price
- IMAB $2.16
- VIGL $7.99
- Analyst Decision
- IMAB Strong Buy
- VIGL Buy
- Analyst Count
- IMAB 2
- VIGL 7
- Target Price
- IMAB $6.00
- VIGL $8.00
- AVG Volume (30 Days)
- IMAB 982.8K
- VIGL 1.6M
- Earning Date
- IMAB 05-15-2025
- VIGL 08-12-2025
- Dividend Yield
- IMAB N/A
- VIGL N/A
- EPS Growth
- IMAB N/A
- VIGL N/A
- EPS
- IMAB N/A
- VIGL N/A
- Revenue
- IMAB N/A
- VIGL N/A
- Revenue This Year
- IMAB N/A
- VIGL N/A
- Revenue Next Year
- IMAB N/A
- VIGL N/A
- P/E Ratio
- IMAB N/A
- VIGL N/A
- Revenue Growth
- IMAB N/A
- VIGL N/A
- 52 Week Low
- IMAB $0.60
- VIGL $1.31
- 52 Week High
- IMAB $3.08
- VIGL $8.00
- Technical
- Relative Strength Index (RSI)
- IMAB 50.70
- VIGL 88.87
- Support Level
- IMAB $2.00
- VIGL $7.86
- Resistance Level
- IMAB $2.95
- VIGL $7.96
- Average True Range (ATR)
- IMAB 0.34
- VIGL 0.02
- MACD
- IMAB -0.08
- VIGL -0.18
- Stochastic Oscillator
- IMAB 15.79
- VIGL 93.33
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.